Trade SCYNEXIS, Inc. - SCYX CFD
Add to favourite- Summary
- Historical Data
- Events
- Ownership
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 1.7 |
| Open* | 1.73 |
| 1-Year Change* | -23.79% |
| Day's Range* | 1.68 - 1.74 |
| 52 wk Range | N/A |
| Average Volume (10 days) | N/A |
| Average Volume (3 months) | N/A |
| Market Cap | N/A |
| P/E Ratio | N/A |
| Shares Outstanding | N/A |
| Revenue | N/A |
| EPS | N/A |
| Dividend (Yield %) | N/A |
| Beta | N/A |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 4, 2023 | 1.70 | -0.01 | -0.58% | 1.71 | 1.75 | 1.64 |
| Dec 1, 2023 | 1.67 | 0.05 | 3.09% | 1.62 | 1.69 | 1.56 |
| Nov 30, 2023 | 1.66 | 0.12 | 7.79% | 1.54 | 1.66 | 1.54 |
| Nov 29, 2023 | 1.53 | -0.01 | -0.65% | 1.54 | 1.60 | 1.53 |
| Nov 28, 2023 | 1.57 | -0.02 | -1.26% | 1.59 | 1.63 | 1.56 |
| Nov 27, 2023 | 1.63 | 0.03 | 1.87% | 1.60 | 1.67 | 1.59 |
| Nov 24, 2023 | 1.63 | 0.03 | 1.87% | 1.60 | 1.66 | 1.60 |
| Nov 22, 2023 | 1.60 | -0.01 | -0.62% | 1.61 | 1.66 | 1.56 |
| Nov 21, 2023 | 1.63 | 0.03 | 1.87% | 1.60 | 1.65 | 1.60 |
| Nov 20, 2023 | 1.63 | 0.05 | 3.16% | 1.58 | 1.64 | 1.49 |
| Nov 17, 2023 | 1.59 | 0.04 | 2.58% | 1.55 | 1.64 | 1.54 |
| Nov 16, 2023 | 1.55 | -0.04 | -2.52% | 1.59 | 1.63 | 1.45 |
| Nov 15, 2023 | 1.64 | 0.00 | 0.00% | 1.64 | 1.71 | 1.63 |
| Nov 14, 2023 | 1.69 | -0.04 | -2.31% | 1.73 | 1.77 | 1.64 |
| Nov 13, 2023 | 1.69 | 0.03 | 1.81% | 1.66 | 1.75 | 1.66 |
| Nov 10, 2023 | 1.68 | 0.01 | 0.60% | 1.67 | 1.68 | 1.64 |
| Nov 9, 2023 | 1.67 | -0.15 | -8.24% | 1.82 | 1.82 | 1.65 |
| Nov 8, 2023 | 1.82 | 0.05 | 2.82% | 1.77 | 1.83 | 1.76 |
| Nov 7, 2023 | 1.84 | 0.10 | 5.75% | 1.74 | 1.85 | 1.74 |
| Nov 6, 2023 | 1.74 | -0.14 | -7.45% | 1.88 | 1.88 | 1.72 |
SCYNEXIS, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
SCYNEXIS, Inc. Company profile
About SCYNEXIS Inc
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous oral agent for multiple fungal indications in both the community and hospital settings. It has received the acceptance letter from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). The FDA has conditionally approved Brexafemme as the brand name for oral ibrexafungerp for vaginal yeast infections. It is also continuing late-stage clinical development for the prevention of recurrent VVC, as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.
Financial summary
BRIEF: For the nine months ended 30 September 2021, SCYNEXIS Inc revenues increased from $0K to $12.6M. Net loss decreased 71% to $3.6M. Revenues reflect Revenue increase from $0K to $12.1M. Lower net loss reflects Warrant liabilities fair value adjustmen increase from $16.1M to $35.4M (income), Research and development - Balancing decrease of 40% to $15.6M (expense), Other expense decrease from $622K (expense) to $0K.
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com